Sign in

You're signed outSign in or to get full access.

2B

2seventy bio, Inc. (TSVT)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 2024: Total revenues were $2.9M; net loss was $19.5M; diluted EPS was $(0.37); year-end cash, cash equivalents, and marketable securities were $183.6M .
  • Abecma U.S. revenue was $59M in Q4 2024 and $242M for FY 2024, within prior guidance; Q4 was impacted by higher deferrals of infusions into 2025 .
  • TSVT entered a definitive agreement to be acquired by Bristol Myers Squibb at $5.00 per share (all-cash), with closing targeted for Q2 2025; TSVT withdrew 2025 guidance and did not host a Q4 call .
  • Operational discipline continued: R&D and SG&A each declined sharply YoY in Q4; share of collaboration loss was ~$3.3M in Q4 as cost structure was streamlined .

What Went Well and What Went Wrong

What Went Well

  • Abecma FY U.S. revenue reached $242M, meeting the previously issued $240–$250M range; management emphasized continued growth in CAR‑T usage in multiple myeloma .
  • Cost controls delivered: Q4 R&D was $8.7M (vs $51.2M in Q4 2023) and SG&A was $8.5M (vs $16.2M in Q4 2023), reflecting the strategic realignment and asset sales completed earlier in 2024 .
  • CEO tone: “2024 was a pivotal year… streamline cost structure and focus solely on Abecma… Together with BMS, we remain committed to expanding the reach of this important therapy” .

What Went Wrong

  • Q4 top-line softness: Total revenues fell to $2.9M and Abecma revenue slowed to $59M due to holiday seasonality and deferrals of infusions into 2025 .
  • Collaboration economics: TSVT recorded a ~$3.3M share of collaboration loss in Q4, underscoring fixed-cost intensity of the U.S. co‑commercialization .
  • Visibility reduced: In light of the BMS transaction, TSVT did not host a Q4 earnings call and withdrew 2025 financial guidance, limiting near-term estimate anchors and narrative clarity .

Financial Results

Consolidated P&L and EPS (USD)

MetricQ2 2024Q3 2024Q4 2024
Total Revenues ($USD Millions)$9.0 $13.5 $2.9
Net Income (Loss) ($USD Millions)$24.9 $(9.9) $(19.5)
Diluted EPS ($USD)$0.45 $(0.19) $(0.37)
EBIT / Loss from Operations ($USD Millions)$(27.1) $(13.9) $(23.3)
R&D Expense ($USD Millions)$16.0 $8.3 $8.7
SG&A Expense ($USD Millions)$9.9 $12.9 $8.5

Notes: EBIT equals reported “Loss from operations”; Q2 net income reflects the $48.0M gain on the Novo Nordisk transaction .

Abecma U.S. Commercial Revenue (Quarterly)

MetricQ2 2024Q3 2024Q4 2024
Abecma U.S. Revenue ($USD Millions)$54 $77 $59

Management indicated Q4 was impacted by higher deferrals into 2025 .

Revenue Components

Revenue ComponentQ2 2024Q3 2024Q4 2024
Service Revenue ($USD Thousands)$4,621 $2,850 $2,926
Collaborative Arrangement Revenue ($USD Thousands)$4,346 $10,684 —
Royalty and Other Revenue ($USD Thousands)— — —
Share of Collaboration Loss ($USD Thousands)— — $3,323

Cash & Balance Sheet

MetricQ2 2024Q3 2024Q4 2024
Cash, Cash Equivalents & Marketable Securities ($USD Millions)$201.9 $192.4 $183.6
Total Assets ($USD Millions)$517.9 $503.8 $479.5
Total Liabilities ($USD Millions)$283.1 $275.7 $268.7
Total Stockholders’ Equity ($USD Millions)$234.8 $228.1 $210.8

KPIs and Operational Items

KPIQ2 2024Q3 2024Q4 2024
Net Cash Burn ($USD Millions)Revised FY net cash spend guidance to $40–$60 for 2024 Burn rate ~$10 for the quarter (management comment) Net cash burn ~$9 for the quarter
Manufacturing Success RateReliable manufacturing highlighted; high rates of in-spec product “North of 95%” success rate (CFO) Not disclosed

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Abecma U.S. RevenueFY 2024~$240–$250M (Nov guidance) $242M actual (prelim) Maintained and achieved
Net Cash SpendFY 2024Lowered to $40–$60M (Aug) Reiterated $40–$60M (Nov) Maintained
Operating Breakeven ThresholdOngoing~<$400M U.S. sales (prior) “Closer to $300M” (updated) Lowered
2025 GuidanceFY 2025Path to quarterly breakeven by end of 2025 (prelim comment) No 2025 guidance; no Q4 call due to transaction Withdrawn
KarMMa‑9 EnrollmentN/ADiscontinue enrollment; >$80M anticipated savings Focus on Abecma and high‑need patients Maintained decision

Earnings Call Themes & Trends

TopicPrevious Mentions (Q2 2024)Previous Mentions (Q3 2024)Current Period (Q4 2024)Trend
Product performance and demandModest revenue growth; double‑digit apheresis increase; return to growth in H2 42% sequential Abecma growth; class share building; third‑line uptake Q4 Abecma $59M; deferrals into 2025 noted Growth with seasonal dip
Manufacturing and marginsReliable, rapid turnaround; high in‑spec rates Manufacturing success >95%; fixed‑cost leverage supports margin Not discussedImproving through Q3
Safety and bridgingEmphasis on differentiated safety; importance of bridging therapy Continued messaging on safety profile and bridging; penetration <25% of 3L USPI safety info reiterated in Q4 release Consistent messaging
R&D/portfolio changesRegeneron/Novo asset sales completed; focus on Abecma Discontinued KarMMa‑9 to conserve >$80M; path to breakeven Sole focus on Abecma; merger announced Streamlined operations
Guidance/toneRevised net cash spend to $40–$60M; cautious but constructive Path to breakeven; breakeven threshold lowered No 2025 guidance; no Q4 call Reduced visibility due to transaction
Strategic optionalityBuild toward breakeven to enable options “One step closer to breaking even” with optionality Tender offer at $5.00/share by BMS Culminates in sale process

Management Commentary

  • CEO: “2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure and focus solely on Abecma… Together with BMS, we remain committed to expanding the reach of this important therapy” .
  • CFO (Q3): “We see really strong manufacturing success rate north of 95%… a strong sales quarter pulls through from a margin perspective, given the high fixed cost nature of the business” .
  • CEO (Q3): Penetration opportunity remains: “We’re still… less than 25% penetrated in the overall third line setting… plenty of room to grow” .
  • CEO (Q2): Strategic focus: “We succeeded in dramatically reducing our cost structure… enabling us to focus 100%… on ABECMA” .

Q&A Highlights

  • Breakeven threshold lowered: CFO now views the breakeven sales level “closer to $300M” vs prior ~$400M, reflecting cost takeout and margin improvements .
  • Seasonality and apheresis trajectory: Q4 apheresis impacted by holidays; underlying demand remains constructive with third‑line approval driving uptake .
  • Safety differentiation and sequencing: Physicians weigh delayed neurotoxicity risks; ABECMA’s manageable safety profile and emphasis on effective bridging support choice and earlier sequencing .
  • Market penetration: Management estimates <25% penetration in third‑line, highlighting runway for CAR‑T class share growth .

Estimates Context

  • Wall Street consensus (S&P Global/Capital IQ) was unavailable due to missing mapping for TSVT, so a direct comparison of Q4 actuals versus consensus could not be produced at this time. As a result, “vs estimates” columns are omitted and narrative comparisons to consensus are not provided [SpgiEstimatesError].

Key Takeaways for Investors

  • Abecma execution: FY 2024 U.S. revenue of $242M hit guidance; Q4 softness was seasonal/deferral‑driven, suggesting revenue may rebound as deferred infusions complete in 2025 .
  • Fixed‑cost leverage: Manufacturing success >95% and improved margins point to better collaboration economics as volumes grow; breakeven threshold lowered to “closer to $300M” .
  • Streamlined Opex: Q4 R&D and SG&A down ~83% and ~48% YoY, respectively, positioning TSVT for improved cash burn and operating leverage in the Abecma‑only model .
  • Reduced visibility from transaction: No Q4 call and withdrawn 2025 guidance constrain near‑term estimate anchors; however, the $5.00/share tender offer sets a valuation floor and defines the near‑term catalyst path .
  • Narrative drivers: Safety/bridging efficacy messaging versus competitors, third‑line market under‑penetration, and manufacturing reliability remain core to commercial momentum .
  • Collaboration P&L sensitivity: Share of collaboration loss in Q4 ($3.3M) underscores the importance of volume scale for margin realization within the U.S. profit‑share structure .
  • Tactical setup: Near‑term trading centers on deal completion risk/timing and any interim Abecma demand signals; medium‑term thesis (pre‑close) hinges on CAR‑T category growth and TSVT/BMS execution in the third‑line setting .